MX2019005466A - Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. - Google Patents

Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.

Info

Publication number
MX2019005466A
MX2019005466A MX2019005466A MX2019005466A MX2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A MX 2019005466 A MX2019005466 A MX 2019005466A
Authority
MX
Mexico
Prior art keywords
formulation
subject
hypercholesterolemia
hypertension
pharmaceutically acceptable
Prior art date
Application number
MX2019005466A
Other languages
English (en)
Spanish (es)
Inventor
Thai Ngoc
Pollett Jonathan
Original Assignee
Imagine Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imagine Pharma filed Critical Imagine Pharma
Publication of MX2019005466A publication Critical patent/MX2019005466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2019005466A 2016-11-13 2017-11-13 Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia. MX2019005466A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421332P 2016-11-13 2016-11-13
PCT/US2017/061343 WO2018089909A1 (en) 2016-11-13 2017-11-13 Compositions and methods for treating diabetes, hypertension and hypercholesterolemia

Publications (1)

Publication Number Publication Date
MX2019005466A true MX2019005466A (es) 2019-10-02

Family

ID=62107069

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005466A MX2019005466A (es) 2016-11-13 2017-11-13 Composiciones y metodos para tratar diabetes, hipertension e hipercolesterolemia.

Country Status (9)

Country Link
US (2) US10548941B2 (enExample)
EP (1) EP3538124A4 (enExample)
JP (3) JP2020502056A (enExample)
KR (1) KR102497242B1 (enExample)
CN (1) CN110087666B (enExample)
AU (2) AU2017357052B2 (enExample)
BR (1) BR112019009511A2 (enExample)
MX (1) MX2019005466A (enExample)
WO (1) WO2018089909A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3538124A4 (en) * 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
BR112020013845A2 (pt) * 2018-01-09 2020-12-01 Imagine Pharma, Llc polipeptídeo ou formulação, métodos para modulação de crescimento celular endotelial e para tratamento de uma doença, e, uso de um polipeptídeo ou formulação.
MX2020014242A (es) * 2018-06-25 2021-05-27 Imagine Pharma Llc Composiciones y métodos para propagar las células de islotes productoras de insulina y usos terapéuticos de las mismas.
CN110974943A (zh) * 2019-12-09 2020-04-10 广东药科大学 一种口服胰岛素药物制剂及其制备方法
CN116685344A (zh) * 2020-12-08 2023-09-01 想象制药有限责任公司 治疗伤口的组合物和方法
AU2022349361A1 (en) * 2021-09-22 2024-03-07 Imagine Pharma Llc Compositions and methods for propogating insulin and glucagon secreting cells from type 1 diabetic pancreatic tissue and therapeutic uses thereof
US20250388638A1 (en) * 2021-12-11 2025-12-25 Imagine Pharma Llc Compositions and methods for oral delivery
WO2025207834A1 (en) * 2024-03-28 2025-10-02 Imagine Pharma Llc Dietary supplements, compositions, and uses thereof for increasing telomerase activity and extending telomere length

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4025395B2 (ja) * 1997-04-09 2007-12-19 花王株式会社 新規ペクチン酸リアーゼ
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AUPR311601A0 (en) * 2001-02-15 2001-03-08 Adp Pharmaceutical Pty Limited Matrix gene expression in chondrogenesis
US20050118151A1 (en) * 2001-05-29 2005-06-02 Syddansk Universitet Proteins in diabetes proteome anlysis
WO2003068908A2 (en) * 2001-07-10 2003-08-21 Gene Logic, Inc. Cardiotoxin molecular toxicology modeling
EP2275127B1 (en) * 2002-04-02 2012-09-19 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
EP1656155A2 (en) * 2003-06-02 2006-05-17 Ohio University Use of genes differentially expressed during aging of liver for treatment and diagnosis
JP2005245202A (ja) * 2004-03-01 2005-09-15 Japan Science & Technology Agency ヒトＴＦＩＩＥαの新規な亜鉛結合ドメインの構造的特徴および機能
WO2008127813A1 (en) * 2007-03-09 2008-10-23 Hiberna Corporation Hibernation-related genes and proteins, activators and inhibitors thereof and methods of use
WO2010129023A2 (en) * 2009-04-28 2010-11-11 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2012054739A2 (en) * 2010-10-21 2012-04-26 New York University Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding
CA2817851A1 (en) * 2010-11-12 2012-05-18 The Johns Hopkins University Albumin-bound protein/peptide complex as a biomarker for disease
ES2569185T3 (es) 2011-03-01 2016-05-09 Nucana Biomed Limited Derivados de fosforamidato de 5-fluoro-2'-desoxiuridina para uso en el tratamiento del cáncer
SG11201602012RA (en) * 2013-09-25 2016-04-28 Pronutria Inc Compositions and formulations for maintaining and increasing muscle mass, strength, and performance and methods of production and use thereof
CN106687128B (zh) * 2014-10-31 2022-05-10 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
US20190000923A1 (en) * 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3538124A4 (en) 2016-11-13 2020-07-22 Imagine Pharma COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES, HYPERTENSION AND HYPERCHOLESTEROLEMIA
BR112020013845A2 (pt) * 2018-01-09 2020-12-01 Imagine Pharma, Llc polipeptídeo ou formulação, métodos para modulação de crescimento celular endotelial e para tratamento de uma doença, e, uso de um polipeptídeo ou formulação.

Also Published As

Publication number Publication date
US20200222499A1 (en) 2020-07-16
US10751384B2 (en) 2020-08-25
AU2022203741A1 (en) 2022-06-23
US20180133280A1 (en) 2018-05-17
US10548941B2 (en) 2020-02-04
JP7711967B2 (ja) 2025-07-23
WO2018089909A1 (en) 2018-05-17
BR112019009511A2 (pt) 2019-07-30
AU2022203741B2 (en) 2024-02-15
AU2017357052B2 (en) 2022-03-24
KR20190084070A (ko) 2019-07-15
JP2025163025A (ja) 2025-10-28
CN110087666A (zh) 2019-08-02
EP3538124A1 (en) 2019-09-18
CN110087666B (zh) 2024-04-30
EP3538124A4 (en) 2020-07-22
JP2020502056A (ja) 2020-01-23
JP2023071670A (ja) 2023-05-23
AU2017357052A1 (en) 2019-05-02
CA3041362A1 (en) 2018-05-17
KR102497242B1 (ko) 2023-02-09

Similar Documents

Publication Publication Date Title
RU2471867C2 (ru) Гиалуронидаза и способ ее применения
BR112019009511A2 (pt) polipeptídeo isolado, formulação, medicamento, uso de pelo menos um polipeptídeo, e, método de tratamento.
PH12021552351A1 (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
IL308807B2 (en) Combination therapy for treating cancer
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
ATE258444T1 (de) Therapeutische chemokine rezeptor antagonisten
EP3744340A3 (en) Compositions and methods for treating cancer
WO2012012600A3 (en) Peptide compounds for regulating the complement system
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
RU2011108486A (ru) ПРИМЕНЕНИЕ ПРОИЗВОДНЫХ ПЕПТИДА Wnt5-a ДЛЯ ЛЕЧЕНИЯ МЕЛАНОМЫ И РАКА ЖЕЛУДКА
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
PH12015501373A1 (en) Injectable depot formulation comprising optically active tolvaptan and process of producing the same
WO2008103378A3 (en) Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
NZ614557A (en) Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
MX2013003523A (es) Composicion farmaceutica de dosis baja.
FI3998067T3 (fi) Koostumukset ja menetelmät homokystinurian hoitoon
MX2015007402A (es) Fusion de hormona de crecimiento humano y albumina, formulacion y usos de los mismos.
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
RU2015119472A (ru) Терапевтическое средство для бокового амиотрофического склероза
EA200700178A1 (ru) Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения
AU2018260628A1 (en) Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
MX2025005154A (es) Formulaciones orales compactables de ibutamoren.
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides